key: cord-0017284-dufnecmh authors: Giguère, Katia; Eaton, Jeffrey W; Marsh, Kimberly; Johnson, Leigh F; Johnson, Cheryl C; Ehui, Eboi; Jahn, Andreas; Wanyeki, Ian; Mbofana, Francisco; Bakiono, Fidèle; Mahy, Mary; Maheu-Giroux, Mathieu title: Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data date: 2021-03-02 journal: Lancet HIV DOI: 10.1016/s2352-3018(20)30315-5 sha: abb6299c6b14f0bf297dc11a65d22e11528c328f doc_id: 17284 cord_uid: dufnecmh BACKGROUND: Monitoring knowledge of HIV status among people living with HIV is essential for an effective national HIV response. This study estimates progress and gaps in reaching the UNAIDS 2020 target of 90% knowledge of status, and the efficiency of HIV testing services in sub-Saharan Africa, where two thirds of all people living with HIV reside. METHODS: For this modelling study, we used data from 183 population-based surveys (including more than 2·7 million participants) and national HIV testing programme reports (315 country-years) from 40 countries in sub-Saharan Africa as inputs into a mathematical model to examine trends in knowledge of status among people living with HIV, median time from HIV infection to diagnosis, HIV testing positivity, and proportion of new diagnoses among all positive tests, adjusting for retesting. We included data from 2000 to 2019, and projected results to 2020. FINDINGS: Across sub-Saharan Africa, knowledge of status steadily increased from 5·7% (95% credible interval [CrI] 4·6–7·0) in 2000 to 84% (82–86) in 2020. 12 countries and one region, southern Africa, reached the 90% target. In 2020, knowledge of status was lower among men (79%, 95% CrI 76–81) than women (87%, 85–89) across sub-Saharan Africa. People living with HIV aged 15–24 years were the least likely to know their status (65%, 62–69), but the largest gap in terms of absolute numbers was among men aged 35–49 years, with 701 000 (95% CrI 611 000–788 000) remaining undiagnosed. As knowledge of status increased from 2000 to 2020, the median time to diagnosis decreased from 9·6 years (9·1–10) to 2·6 years (1·8–3·5), HIV testing positivity declined from 9·0% (7·7–10) to 2·8% (2·1–3·9), and the proportion of first-time diagnoses among all positive tests dropped from 89% (77–96) to 42% (30–55). INTERPRETATION: On the path towards the next UNAIDS target of 95% diagnostic coverage by 2025, and in a context of declining positivity and yield of first-time diagnoses, disparities in knowledge of status must be addressed. Increasing knowledge of status and treatment coverage among older men could be crucial to reducing HIV incidence among women in sub-Saharan Africa, and by extension, reducing mother-to-child transmission. FUNDING: Steinberg Fund for Interdisciplinary Global Health Research (McGill University); Canadian Institutes of Health Research; Bill & Melinda Gates Foundation; Fonds the recherche du Québec—Santé; UNAIDS; UK Medical Research Council; MRC Centre for Global Infectious Disease Analysis; UK Foreign, Commonwealth & Development Office. . Progress in HIV testing related outcomes in Western Africa stratified by sex and age group, 2000-2020. ... 12 Table S6 . Progress in HIV testing related outcomes in Central Africa stratified by sex and age group, 2000-2020. .... 13 Table S7 . Progress in HIV testing related outcomes in Eastern Africa stratified by sex and age group, 2000-2020. .... 14 Table S8 Text S1. Estimating diagnosis delays. From the annual sex-, age-, HIV testing history-, and CD4 cell count-specific testing rates, we calculated several cross-sectional indicators using period life table methods 17 that account for the competing risk of AIDS-related death. For each stratum, we proceed by initializing the life table at infection (time 0: t0) using the age-specific CD4 cell count distribution at infection (either ≥500 or 350-499 CD4 cells per µL) as is used in Spectrum. We then calculate the number of individuals that will either receive a positive test result or die of AIDS-related cause at each time step (∆ = 0.1 year), accounting for CD4 cell count progression. As these are period life tables, estimates reflect the distribution of time to diagnosis if a person who seroconverted in year y experienced the HIV testing rates by age and CD4 category estimated for the that year for their remaining lifetime. Specifically, the life tables are constructed using the following equations (for t≥t0): where is the number of individuals who seroconverted during calendar year y, from sex k, age i, CD4 cell count s (where 1 indexes CD4 counts of ≥500 cells per µL, 2 for 350-499, 3 for 250-349, 4 for 200-249, 5 for 100-199, 6 for 50-99, and 7 for <50 CD4 cells per µL), and testing history u, at time t since infection; is is the CD4 cell count progression rates; τ [ ] [ ] is the HIV testing rate specific to sex k, age ( [ ] , accounting for aging as a function of time t), CD4 cell count ( [ ] , as CD4 cell count decreases as a function of time t), and testing history (u) that were estimated for the calendar year y in which an individual seroconverted; and [ ] is the age-(at infection) and CD4 cell count-specific AIDS-related mortality rate. After constructing the life table, we calculated the median time between HIV infection and diagnosis or AIDS-related death ( ) by finding the time t after which more than half of the newly seroconverted individuals had either been diagnosed or died of HIV ( ( )): Finally, the probability of getting tested within one year of infection ( ), and of getting tested before reaching a CD4 cell count threshold lower than 350 cells per µL (s=3) ( ) were estimated by accounting for the competing risk of AIDS-related death using, respectively: For each calendar year between 2000 and 2020, we estimated these indicators for the 16 age/sex/testing history strata separately. They were then aggregated to the desired level of aggregation (e.g., age, sex, country, region) by weighting each stratum by the estimated number of new HIV infections in that stratum for that year (obtained from Spectrum). The positivity corresponds to the proportion of positive tests among all tests, while diagnosis yield corresponds to the proportion of new diagnoses among all tests. HIV prevalence is expressed among the total population aged 15+ years. The shaded areas correspond to the 95% credible intervals. Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made. List the funding sources for the work. 1 For all data inputs from multiple sources that are synthesized as part of the study: 3 Describe how the data were identified and how the data were accessed. 3 4 Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. 3 5 Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant. 3, Figure 1 , Table S1 (appendix pp 6-8) Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5). For data inputs that contribute to the analysis but were not synthesized as part of the study: 7 Describe and give sources for any other data inputs. 3, Figure 1 , Table S1 (appendix pp 6-8) For all data inputs: 8 Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. 9 (links provided in the Data sharing section) Provide a conceptual overview of the data analysis method. A diagram may be helpful. Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s). Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis. State how analytic or statistical source code used to generate estimates can be accessed. 4, 9 Provide published estimates in a file format from which data can be efficiently extracted. Table 1, Tables S3-S8 (appendix pp 11-16) 16 Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals). Tables and Figures 17 Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates. 18 Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates. Some small discrepancies could be observed between sub-Saharan Africa estimate and the sum of Western, Central, Eastern, and Southern regions estimates because each region-specific estimate is based on independent draws of posterior estimates. For each country, Shiny90 posterior estimates of the total number of HIV tests (A), the total number of positive tests (B), the proportion reporting having ever been tested among the HIV negative population (C), among people living with HIV (PLHIV; D), and overall (E) are compared to available HTS program and survey data. On all graphs, the lines correspond to the median of the posterior estimates, whereas the shaded areas correspond to the 95% credible intervals. Black dots on graphs A and B correspond to the HIV testing services program data for the overall number of tests, and for the number of positive tests, respectively. The points on the graphs C to E correspond to survey estimates of the proportion of men (circles) and women (squares) reporting having ever been tested among the HIV negative population (C), PLHIV (D), and overall population (E). The lines correspond to the 95% credible intervals of the surveys estimates. For countries denoted by an asterisk (*), surveys for which datasets are not yet publicly available are not plotted. However, these estimates were included in model calibration and in the knowledge of status estimates reported to UNAIDS. The Gambia Global AIDS Response Progress Report Rapport national de la riposte VIH/SIDA 2014 -Progrès Report -Status of the national response to the 2001 declaration of commitment on HIV and AIDS Report -Status of the national response to the 2001 declaration of commitment on HIV and AIDS Report -Status of the national response to the 2001 declaration of commitment on HIV and AIDS Report -Status of the national response to the 2001 declaration of commitment on HIV and AIDS Report -Status of the national response to the 2001 declaration of commitment on HIV and AIDS Did the 2014 Ebola outbreak in Liberia affect HIV testing, linkage to care and ART initiation? Rapport sur la réponse face au VIH et au SIDA à Madagascar Rapport sur la réponse face au VIH et au SIDA à Madagascar Rapport sur la réponse face au VIH et au SIDA à Madagascar Rapport sur la réponse face au VIH et au SIDA à Madagascar National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the "first 90" from program and survey data National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the "first 90" from program and survey data Republic of Namibia Ministry of Health and Social Services, United Nations General Assembly Special Session (UNGASS) Country Report -Reporting Period Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA -Sénégal Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA -Sénégal Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA -Sénégal Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Suivi de la déclaration d'engagement sur le VIH et le SIDA -Rapport Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles pdf Zambia 2006 National AIDS Council, Zambia country report -Monitoring the declaration of commitment on HIV and AIDS and the universal access